Wed, November 27, 2024
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Brian Stokes
Caroline Cummings
[ Tue, Nov 26th 2024 ] - Brian Stokes
Trust Matters in Cabinet Picks
Mon, November 25, 2024
Sun, November 24, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Thu, April 23, 2009
Mon, February 2, 2009
[ Mon, Feb 02nd 2009 ] - Nathan Burkes
Is Obama a rock star?
Fri, January 30, 2009

The Medipattern Corporation: RETRANSMISSION: Medipattern Provides Additional Information for Previously Announced Financing


//business-finance.news-articles.net/content/200 .. ormation-for-previously-announced-financing.html
Published in Business and Finance on Monday, January 12th 2009 at 7:57 GMT, Last Modified on 2009-01-12 07:57:45 by Market Wire   Print publication without navigation


TORONTO, ONTARIO--(Marketwire - Jan. 12, 2009) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern" or the "Company") (TSX VENTURE:MKI), announced that further to the closing of the convertible debenture financing disclosed on December 24, 2008, the number of shares issuable by Medipattern on conversion to be determined in the context of the market is subject to a maximum of 1,020,000 shares.

About The Medipattern Corporation

Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its CADenzaTM CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: [ www.medipattern.com ].

CADenzaTM is a trademark of The Medipattern Corporation. B-CAD® and Medipattern® are registered marks of The Medipattern Corporation. BI-RADS® is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at [ www.sedar.com ]). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.



Publication Contributing Sources